JJK Holdings Ltd. Acquires $7,878,792 Convertible Debenture Of Noveris Health Sciences Inc.; Filing Of Early Warning Reports By JJK Holdings Ltd.

JJK Holdings purchased a CAD 7,878,792 convertible debenture in Noveris Health Sciences from Pioneer Garage, maturing October 14, 2026 and convertible at the greater of a 20‑day VWAP or the CSE minimum. Using the recent CSE close of $0.185 as an illustrative conversion price, the debenture could convert into 42,588,065 common shares, equal to roughly 97.18% of the company’s outstanding shares (current issued shares: 1,235,061), prompting Early Warning filings and creating the prospect of material dilution and a potential change of control. JJK may transfer or further transact in the debenture and will update disclosures as required.

Analysis

Market structure: JJK’s purchase of a CAD 7.88M convertible debenture implies a possible one-holder control scenario — conversion could create ~42.6M shares equal to ~97.18% of outstanding at a ~$0.185 reference price — which directly benefits the debtholder (control optionality) and substantially dilutes current retail/minority shareholders. Competitive dynamics in the microcap biotech space worsen for NVRS: pricing power of current equity collapses if conversion floods float; comparably capitalized peers remain unaffected unless this triggers sector-wide risk-off in small-cap psychedelics. Cross-asset impact is concentrated: NVRS equity volatility should spike (options implied vol up), credit-like instruments (the debenture) get priced for control value, FX/commodities immaterial.

Risk assessment: Tail risks include (1) immediate conversion and squeeze-out before Oct 14, 2026 wiping public float, (2) CSE or regulator forcing suspension/delisting, (3) activist/related-party litigation. Immediate (days): tradeable liquidity shock and headline-driven price moves; short-term (weeks–months): dilution risk as VWAP moves; long-term (quarters–years): clinical readouts drive fundamental reset. Hidden dependencies: conversion price is the greater of 20-day VWAP or CSE minimum — a rising VWAP reduces dilution; JJK’s intention to distribute debenture adds execution risk. Key catalysts: SEDAR+ early-warning updates, any transfer of debenture, VWAP trends, clinical milestones, Oct 14, 2026 maturity.

Trade implications: Primary direct play is a short of NVRS (CSE:NVRS / OTC:MYCOF) size-limited due to borrow and illiquidity; preferable to use put structures where available. Pair trade: short NVRS and long IBB (iShares Nasdaq Biotechnology ETF) to isolate idiosyncratic dilution risk. Options strategy: buy 3–6 month put spreads or long-dated puts to cap capital at known losses; if options absent, use small short equity with strict stops. Entry window: act within 5 trading days on continued negative VWAP/filings; re-evaluate at any debenture transfer or if 20-day VWAP > $0.30.

Contrarian angles: Consensus assumes guaranteed destruction of value — missing is the scenario where JJK converts to obtain control and then takes the company private or executes a tender at a premium; that would create a binary upside. Another underappreciated path: a clinical success before conversion could lift 20-day VWAP materially, materially reducing dilution and flipping the trade. Historical parallels: post-conversion control situations in microcap biotechs often lead to delisting or buyouts within 6–12 months; outcomes vary widely, so position sizes must be tiny and time-bound.

Key Decisions for Investors

• Establish a tactical short position in NVRS (CSE:NVRS / OTC:MYCOF) sized 0.5–1.0% of NAV within 5 trading days; target a 70% downside over 3 months, set a hard stop-loss at +30% adverse move and monitor borrow availability daily.
• If liquid options exist, buy 3–6 month put spreads on MYCOF (e.g., buy ATM-ish put, sell lower strike to finance) limiting max risk to ~0.25% NAV; if no options, use convertible short-sized equity (as above) to replicate downside exposure.
• Establish a relative-value pair: short NVRS and allocate equal notional long to IBB (ticker IBB) sized 0.5% NAV to isolate idiosyncratic dilution risk; reweight if SEDAR+ filings show debenture transfer or intent to convert.
• Monitor two thresholds and act: (A) if 20-day VWAP > $0.30 (about +62% from $0.185) reduce short by 50% immediately; (B) if SEDAR+ shows debenture transfer or a registered convertible-to-equity conversion notice, cover shorts fully and reassess within 48 hours.
• Consider a contrarian speculative long of 0.25% NAV only if company announces a positive clinical milestone or a third-party offer at >$1.00/share within the next 12 months — otherwise avoid new long exposure.